spacer
spacer
Go to PDB code: 
protein ligands metals links
Oxidoreductase PDB id
1tg2
Jmol
Contents
Protein chain
308 a.a. *
Ligands
H2B
Metals
_FE
Waters ×73
* Residue conservation analysis
PDB id:
1tg2
Name: Oxidoreductase
Title: Crystal structure of phenylalanine hydroxylase a313t mutant with 7,8-dihydrobiopterin bound
Structure: Phenylalanine-4-hydroxylase. Chain: a. Fragment: delta nh 1-102-delta cooh 428 human phenylalanine hydroxylase. Synonym: pah, phe-4- monooxygenase. Engineered: yes. Mutation: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Gene: pah. Expressed in: escherichia coli bl21(de3). Expression_system_taxid: 469008.
Resolution:
2.20Å     R-factor:   0.213     R-free:   0.254
Authors: H.Erlandsen,A.L.Pey,A.Gamez,B.Perez,L.R.Desviat,C.Aguado, R.Koch,S.Surendran,S.Tyring,R.Matalon,C.R.Scriver,M.Ugarte, A.Martinez,R.C.Stevens
Key ref:
H.Erlandsen et al. (2004). Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc Natl Acad Sci U S A, 101, 16903-16908. PubMed id: 15557004 DOI: 10.1073/pnas.0407256101
Date:
28-May-04     Release date:   30-Nov-04    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
P00439  (PH4H_HUMAN) -  Phenylalanine-4-hydroxylase
Seq:
Struc:
452 a.a.
308 a.a.*
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 1 residue position (black cross)

 Enzyme reactions 
   Enzyme class: E.C.1.14.16.1  - Phenylalanine 4-monooxygenase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]

      Pathway:
Phenylalanine and Tyrosine Biosynthesis
      Reaction: L-phenylalanine + tetrahydrobiopterin + O2 = L-tyrosine + 4a-hydroxytetrahydrobiopterin
L-phenylalanine
+
tetrahydrobiopterin
Bound ligand (Het Group name = H2B)
corresponds exactly
+ O(2)
= L-tyrosine
+ 4a-hydroxytetrahydrobiopterin
      Cofactor: Iron
Molecule diagrams generated from .mol files obtained from the KEGG ftp site
 Gene Ontology (GO) functional annotation 
  GO annot!
  Biological process     oxidation reduction   2 terms 
  Biochemical function     monooxygenase activity     3 terms  

 

 
    reference    
 
 
DOI no: 10.1073/pnas.0407256101 Proc Natl Acad Sci U S A 101:16903-16908 (2004)
PubMed id: 15557004  
 
 
Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations.
H.Erlandsen, A.L.Pey, A.Gámez, B.Pérez, L.R.Desviat, C.Aguado, R.Koch, S.Surendran, S.Tyring, R.Matalon, C.R.Scriver, M.Ugarte, A.Martínez, R.C.Stevens.
 
  ABSTRACT  
 
Phenylketonuria patients harboring a subset of phenylalanine hydroxylase (PAH) mutations have recently shown normalization of blood phenylalanine levels upon oral administration of the PAH cofactor tetrahydrobiopterin [(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4)]. Several hypotheses have been put forward to explain BH4 responsiveness, but the molecular basis for the corrective effect(s) of BH4 has not been understood. We have investigated the biochemical, kinetic, and structural changes associated with BH4-responsive mutations (F39L, I65T, R68S, H170D, E178G, V190A, R261Q, A300S, L308F, A313T, A373T, V388M, E390G, P407S, and Y414C). The biochemical and kinetic characterization of the 15 mutants studied points toward a multifactorial basis for the BH4 responsiveness; the mutants show residual activity (>30% of WT) and display various kinetic defects, including increased Km (BH4) and reduced cooperativity of substrate binding, but no decoupling of cofactor (BH4) oxidation. For some, BH4 seems to function through stabilization and protection of the enzyme from inactivation and proteolytic degradation. In the crystal structures of a phenylketonuria mutant, A313T, minor changes were seen when compared with the WT PAH structures, consistent with the mild effects the mutant has upon activity of the enzyme both in vitro and in vivo. Truncations made in the A313T mutant PAH form revealed that the N and C termini of the enzyme influence active site binding. Of fundamental importance is the observation that BH4 appears to increase Phe catabolism if at least one of the two heterozygous mutations has any residual activity remaining.
 
  Selected figure(s)  
 
Figure 1.
Fig. 1. PAH mutations covered in this work mapped onto the monomer of a composite model of full-length PAH. Orange represents the regulatory domain (1-142), gray represents the catalytic domain (143-410), and blue represents the oligomerization domain (411-452). The iron at the active site is displayed as a yellow sphere, whereas the tetrahydrobiopterin (BH[4]), thienylalanine (TIH) substrate analog, and protein side chains are colored by individual atom colors (green is carbon, blue is nitrogen, red is oxygen, and yellow is sulfur). The purple regions are considered the pterin-binding regions.
Figure 2.
Fig. 2. (A) Ala-313 environment in wt-PAH composite full-length model. (B) Thr-313 environment in the A313T-dt-PAH·7,8-BH[2] structure. The color scheme is as in Fig. 1.
 

Literature references that cite this PDB file's key reference

  PubMed id Reference
21527427 M.Staudigl, S.W.Gersting, M.K.Danecka, D.D.Messing, M.Woidy, D.Pinkas, K.F.Kemter, N.Blau, and A.C.Muntau (2011).
The interplay between genotype, metabolic state and cofactor treatment governs phenylalanine hydroxylase function and drug response.
  Hum Mol Genet, 20, 2628-2641.  
20492352 A.C.Calvo, T.Scherer, A.L.Pey, M.Ying, I.Winge, J.McKinney, J.Haavik, B.Thöny, and A.Martinez (2010).
Effect of pharmacological chaperones on brain tyrosine hydroxylase and tryptophan hydroxylase 2.
  J Neurochem, 114, 853-863.  
20824346 A.C.Muntau, and S.W.Gersting (2010).
Phenylketonuria as a model for protein misfolding diseases and for the development of next generation orphan drugs for patients with inborn errors of metabolism.
  J Inherit Metab Dis, 33, 649-658.  
20556797 A.Jorge-Finnigan, C.Aguado, R.Sánchez-Alcudia, D.Abia, E.Richard, B.Merinero, A.Gámez, R.Banerjee, L.R.Desviat, M.Ugarte, and B.Pérez (2010).
Functional and structural analysis of five mutations identified in methylmalonic aciduria cblB type.
  Hum Mutat, 31, 1033-1042.  
20714359 C.O.Harding (2010).
New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride.
  Biologics, 4, 231-236.  
20480196 M.I.Flydal, T.C.Mohn, A.L.Pey, J.Siltberg-Liberles, K.Teigen, and A.Martinez (2010).
Superstoichiometric binding of L-Phe to phenylalanine hydroxylase from Caenorhabditis elegans: evolutionary implications.
  Amino Acids, 39, 1463-1475.  
20179079 S.W.Gersting, F.B.Lagler, A.Eichinger, K.F.Kemter, M.K.Danecka, D.D.Messing, M.Staudigl, K.A.Domdey, C.Zsifkovits, R.Fingerhut, H.Glossmann, A.A.Roscher, and A.C.Muntau (2010).
Pahenu1 is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo.
  Hum Mol Genet, 19, 2039-2049.  
19292873 A.Daniele, I.Scala, G.Cardillo, C.Pennino, C.Ungaro, M.Sibilio, G.Parenti, L.Esposito, A.Zagari, G.Andria, and F.Salvatore (2009).
Functional and structural characterization of novel mutations and genotype-phenotype correlation in 51 phenylalanine hydroxylase deficient families from Southern Italy.
  FEBS J, 276, 2048-2059.  
18956252 F.K.Trefz, D.Scheible, H.Götz, and G.Frauendienst-Egger (2009).
Significance of genotype in tetrahydrobiopterin-responsive phenylketonuria.
  J Inherit Metab Dis, 32, 22-26.  
19323589 M.Sanford, and G.M.Keating (2009).
Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia.
  Drugs, 69, 461-476.  
19627172 M.Sanford, and G.M.Keating (2009).
Spotlight on sapropterin in primary hyperphenylalaninemiadagger.
  BioDrugs, 23, 201-202.  
19629656 M.Stojiljkovic, B.Pérez, L.R.Desviat, C.Aguado, M.Ugarte, and S.Pavlovic (2009).
The Missense p.S231F phenylalanine hydroxylase gene mutation causes complete loss of enzymatic activity in vitro.
  Protein J, 28, 294-299.  
18937047 S.F.Dobrowolski, A.L.Pey, R.Koch, H.Levy, C.C.Ellingson, E.W.Naylor, and A.Martinez (2009).
Biochemical characterization of mutant phenylalanine hydroxylase enzymes and correlation with clinical presentation in hyperphenylalaninaemic patients.
  J Inherit Metab Dis, 32, 10-21.  
18596920 A.L.Pey, M.Ying, N.Cremades, A.Velazquez-Campoy, T.Scherer, B.Thöny, J.Sancho, and A.Martinez (2008).
Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria.
  J Clin Invest, 118, 2858-2867.  
17957493 B.Merinero, B.Pérez, C.Pérez-Cerdá, A.Rincón, L.R.Desviat, M.A.Martínez, P.R.Sala, M.J.García, L.Aldamiz-Echevarría, J.Campos, V.Cornejo, M.Del Toro, A.Mahfoud, M.Martínez-Pardo, R.Parini, C.Pedrón, L.Peña-Quintana, M.Pérez, M.Pourfarzam, and M.Ugarte (2008).
Methylmalonic acidaemia: examination of genotype and biochemical data in 32 patients belonging to mut, cblA or cblB complementation group.
  J Inherit Metab Dis, 31, 55-66.  
18498375 C.Harding (2008).
Progress toward cell-directed therapy for phenylketonuria.
  Clin Genet, 74, 97.  
18299955 D.Bercovich, A.Elimelech, J.Zlotogora, S.Korem, T.Yardeni, N.Gal, N.Goldstein, B.Vilensky, R.Segev, S.Avraham, R.Loewenthal, G.Schwartz, and Y.Anikster (2008).
Genotype-phenotype correlations analysis of mutations in the phenylalanine hydroxylase (PAH) gene.
  J Hum Genet, 53, 407-418.  
18230057 K.Michals-Matalon (2008).
Sapropterin dihydrochloride, 6-R-L-erythro-5,6,7,8-tetrahydrobiopterin, in the treatment of phenylketonuria.
  Expert Opin Investig Drugs, 17, 245-251.  
17935162 M.R.Zurflüh, J.Zschocke, M.Lindner, F.Feillet, C.Chery, A.Burlina, R.C.Stevens, B.Thöny, and N.Blau (2008).
Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.
  Hum Mutat, 29, 167-175.  
18538294 S.W.Gersting, K.F.Kemter, M.Staudigl, D.D.Messing, M.K.Danecka, F.B.Lagler, C.P.Sommerhoff, A.A.Roscher, and A.C.Muntau (2008).
Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability.
  Am J Hum Genet, 83, 5.  
18210214 U.Langenbeck (2008).
Classifying tetrahydrobiopterin responsiveness in the hyperphenylalaninaemias.
  J Inherit Metab Dis, 31, 67-72.  
17693159 A.L.Pey, and A.Martinez (2007).
Tetrahydrobiopterin for patients with phenylketonuria.
  Lancet, 370, 462-463.  
17924342 A.L.Pey, F.Stricher, L.Serrano, and A.Martinez (2007).
Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases.
  Am J Hum Genet, 81, 1006-1024.  
17443661 C.R.Scriver (2007).
The PAH gene, phenylketonuria, and a paradigm shift.
  Hum Mutat, 28, 831-845.  
17627389 L.Wang, S.Surendran, K.Michals-Matalon, G.Bhatia, S.Tanskley, R.Koch, J.Grady, S.K.Tyring, R.C.Stevens, F.Guttler, and R.Matalon (2007).
Mutations in the regulatory domain of phenylalanine hydroxylase and response to tetrahydrobiopterin.
  Genet Test, 11, 174-178.  
17334706 R.Matalon, K.Michals-Matalon, G.Bhatia, A.B.Burlina, A.P.Burlina, C.Braga, L.Fiori, M.Giovannini, E.Grechanina, P.Novikov, J.Grady, S.K.Tyring, and F.Guttler (2007).
Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine.
  J Inherit Metab Dis, 30, 153-158.  
16763894 P.T.Clayton (2006).
B6-responsive disorders: a model of vitamin dependency.
  J Inherit Metab Dis, 29, 317-326.  
16988900 R.Matalon, K.Michals-Matalon, G.Bhatia, E.Grechanina, P.Novikov, J.D.McDonald, J.Grady, S.K.Tyring, and F.Guttler (2006).
Large neutral amino acids in the treatment of phenylketonuria (PKU).
  J Inherit Metab Dis, 29, 732-738.  
16378243 X.Zhang, J.M.Beaulieu, R.R.Gainetdinov, and M.G.Caron (2006).
Functional polymorphisms of the brain serotonin synthesizing enzyme tryptophan hydroxylase-2.
  Cell Mol Life Sci, 63, 6.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time.